Canton Strategic Holdings (CNTN) Change in Account Payables (2021 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Change in Account Payables came in at -$687963.0 in Q1 2026, down 1191.95% YoY from $63003.0 in Q1 2025, and down 303.3% on a QoQ basis from $338404.0 in Q4 2025.
Powered by 
Analysis
Canton Strategic Holdings (CNTN) Change in Account Payables (2021 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of Change in Account Payables data on file, last reported at -$687963.0 in Q1 2026.
- Quarterly Change in Account Payables fell 1191.95% year-over-year to -$687963.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$528489.0 (down 431.5% YoY) and the FY2025 annual result came in at $222477.0, up 22.86% from the prior year.
- Change in Account Payables eased to -$687963.0 in Q1 2026, from $338404.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $466532.0 in Q2 2023 to a low of -$687963.0 in Q1 2026.
- A 5-year average of -$27735.0 and a median of -$1720.0 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2024 — Change in Account Payables soared 612.21% — and 2025, when it sank 1363.97%.
- Tracing CNTN's Change in Account Payables over 5 years: stood at $417667.0 in 2022, then tumbled by 155.1% to -$230118.0 in 2023, then soared by 232.9% to $305827.0 in 2024, then gained by 10.65% to $338404.0 in 2025, then slumped by 303.3% to -$687963.0 in 2026.
- The last three Change in Account Payables figures came in at -$687963.0 (Q1 2026), $338404.0 (Q4 2025), and -$111356.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | 529,367.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 529,367.00 |
| Mar 31, 2026 | -687,963.00 |
| Dec 31, 2025 | 338,404.00 |
| Sep 30, 2025 | -445,380.00 |
| Jun 30, 2025 | 266,450.00 |
| Mar 31, 2025 | 63,003.00 |
| Dec 31, 2024 | 305,827.00 |
| Sep 30, 2024 | 8,810.00 |
| Jun 30, 2024 | -218,215.00 |
| Mar 31, 2024 | 84,667.00 |
| Dec 31, 2023 | -230,118.00 |
| Sep 30, 2023 | -1,720.00 |
| Jun 30, 2023 | 466,532.00 |
| Mar 31, 2023 | -280,622.00 |
| Dec 31, 2022 | 358,837.00 |
| Sep 30, 2022 | -22,691.00 |
| Jun 30, 2022 | -37,926.00 |
| Mar 31, 2022 | -498,220.00 |
| Dec 31, 2021 | 140,616.00 |
| Sep 30, 2021 | 61,168.00 |